European Heart Journal

Article	Citations
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	5667
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)	5245
2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	2803
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice	2572
2021 ESC/EACTS Guidelines for the management of valvular heart disease	2175
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension	1115
2020 ESC Guidelines for the management of adult congenital heart disease	949
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy	884
2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death	813
2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease	806
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the Internatio	767
COVID-19 is, in the end, an endothelial disease	679
Reduction of hospitalizations for myocardial infarction in Italy in the COVID-19 era	655
SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe	494
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases	473
2023 ESC Guidelines for the management of acute coronary syndromes	417
Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy	408
An EAPCI Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries in Collaboration with European Society of Cardiology Working Group on Coronary Pathophysiology & Microcircula	396
Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin–angiotensin–aldosterone inhibitors	364
European Society of Cardiology: cardiovascular disease statistics 2021	364
Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis	360
Characteristics and clinical significance of myocardial injury in patients with severe coronavirus disease 2019	353
Pathological features of COVID-19-associated myocardial injury: a multicentre cardiovascular pathology study	348
Valve Academic Research Consortium 3: updated endpoint definitions for aortic valve clinical research	341
2022 ESC Guidelines on cardiovascular assessment and management of patients undergoing non-cardiac surgery	326

Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement	321
Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Ather	318
Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus	316
Association of hypertension and antihypertensive treatment with COVID-19 mortality: a retrospective observational study	287
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure	279
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force	278
Patterns of myocardial injury in recovered troponin-positive COVID-19 patients assessed by cardiovascular magnetic resonance	271
Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine	258
Effect of icosapent ethyl on progression of coronary atherosclerosis in patients with elevated triglycerides on statin therapy: final results of the EVAPORATE trial	257
The ‘Ten Commandments’ for the 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation	250
C-reactive protein and clinical outcomes in patients with COVID-19	249
2023 ESC Guidelines for the management of cardiomyopathies	229
Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement	220
SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions	210
Pulmonary embolism in COVID-19 patients: a French multicentre cohort study	197
Effects of tobacco cigarettes, e-cigarettes, and waterpipe smoking on endothelial function and clinical outcomes	193
Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study	190
Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to ANGPTL3 mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyc	186
Corrigendum to: 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure o	182
COVID-19 kills at home: the close relationship between the epidemic and the increase of out-of-hospital cardiac arrests	179
Left bundle branch area pacing outcomes: the multicentre European MELOS study	175
Time-to-treatment initiation of colchicine and cardiovascular outcomes after myocardial infarction in the Colchicine Cardiovascular Outcomes Trial (COLCOT)	171
2023 ESC Guidelines for the management of endocarditis	168
Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation and coexistent atrial fibrillation – Dual versus triple antithrombotic therapy	165
The neutrophil–lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials	162
Eight-year outcomes for patients with aortic valve stenosis at low surgical risk randomized to transcatheter vs. surgical aortic valve replacement	160
Prevalence of statin intolerance: a meta-analysis	158
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	155
Left ventricular remodelling post-myocardial infarction: pathophysiology, imaging, and novel therapies	154
Isolated tricuspid valve surgery: impact of aetiology and clinical presentation on outcomes	150
Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction	149
Remnant cholesterol predicts cardiovascular disease beyond LDL and ApoB: a primary prevention study	144
A randomized controlled trial of dapagliflozin on left ventricular hypertrophy in people with type two diabetes: the DAPA-LVH trial	143
Cardiovascular health after menopause transition, pregnancy disorders, and other gynaecologic conditions: a consensus document from European cardiologists, gynaecologists, and endocrinologists	141
The Mediterranean diet, plasma metabolome, and cardiovascular disease risk	141
2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes	139
Corrigendum to: 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS)	138
The ESC Clinical Practice Guidelines for the Management of Adult Congenital Heart Disease 2020	132
Heart failure drug treatment: the fantastic four	131
The physical activity paradox in cardiovascular disease and all-cause mortality: the contemporary Copenhagen General Population Study with 104 046 adults	131
Thin-cap fibroatheroma predicts clinical events in diabetic patients with normal fractional flow reserve: the COMBINE OCT–FFR trial	125
Multicentre, randomized comparison of two-stent and provisional stenting techniques in patients with complex coronary bifurcation lesions: the DEFINITION II trial	124
Coronary flow reserve and cardiovascular outcomes: a systematic review and meta-analysis	123
Associations between gut microbiota, faecal short-chain fatty acids, and blood pressure across ethnic groups: the HELIUS study	123
Association between adiposity and cardiovascular outcomes: an umbrella review and meta-analysis of observational and Mendelian randomization studies	122
Joint exposure to various ambient air pollutants and incident heart failure: a prospective analysis in UK Biobank	122
Effect of dapagliflozin on ventricular arrhythmias, resuscitated cardiac arrest, or sudden death in DAPA-HF	122
Causal associations of short and long sleep durations with 12 cardiovascular diseases: linear and nonlinear Mendelian randomization analyses in UK Biobank	121
TRI-SCORE: a new risk score for in-hospital mortality prediction after isolated tricuspid valve surgery	121
Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial	120

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes	120
The European bifurcation club Left Main Coronary Stent study: a randomized comparison of stepwise provisional vs. systematic dual stenting strategies (EBC MAIN)	119
Propionate attenuates atherosclerosis by immune-dependent regulation of intestinal cholesterol metabolism	119
Genome-wide analysis identifies novel susceptibility loci for myocardial infarction	119
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials	118
AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial	115
Multi-organ assessment in mainly non-hospitalized individuals after SARS-CoV-2 infection: The Hamburg City Health Study COVID programme	113
Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial	113
Lifestyle, cardiometabolic disease, and multimorbidity in a prospective Chinese study	111
Empagliflozin in acute myocardial infarction: the EMMY trial	106
Non-linear Mendelian randomization analyses support a role for vitamin D deficiency in cardiovascular disease risk	105
Application of artificial intelligence to the electrocardiogram	103
Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake	102
Combining loop with thiazide diuretics for decompensated heart failure: the CLOROTIC trial	102
Electrocardiogram screening for aortic valve stenosis using artificial intelligence	99
Bariatric surgery and cardiovascular disease: a systematic review and meta-analysis	98
Vulnerable plaques and patients: state-of-the-art	98
Clinical presentation, management, and 6-month outcomes in women with peripartum cardiomyopathy: an ESC EORP registry	97
The risk of cardiac events in patients receiving immune checkpoint inhibitors: a nationwide Danish study	96
EAPCI Position Statement on Invasive Management of Acute Coronary Syndromes during the COVID-19 pandemic	96
Efficacy of a digital therapeutics system in the management of essential hypertension: the HERB-DH1 pivotal trial	96
Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial	95
Long-term outcomes after transcatheter aortic valve implantation in failed bioprosthetic valves	94
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up	93
Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation	93
Ticagrelor alone vs. ticagrelor plus aspirin following percutaneous coronary intervention in patients with non-ST-segment elevation acute coronary syndromes: TWILIGHT-ACS	93
Prevention of aortic dissection and aneurysm via an ALDH2-mediated switch in vascular smooth muscle cell phenotype	91
Combination lipid-lowering therapy as first-line strategy in very high-risk patients	91
Short dual antiplatelet therapy followed by P2Y12 inhibitor monotherapy vs. prolonged dual antiplatelet therapy after percutaneous coronary intervention with second-generation drug-eluting stents: a s	91
Effect of dapagliflozin according to baseline systolic blood pressure in the Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure trial (DAPA-HF)	91
Systematic, early rhythm control strategy for atrial fibrillation in patients with or without symptoms: the EAST-AFNET 4 trial	90
Validation of high bleeding risk criteria and definition as proposed by the academic research consortium for high bleeding risk	89
Pulmonary embolism in patients with COVID-19: incidence, risk factors, clinical characteristics, and outcome	89
Sex differences and temporal trends in aortic dissection: a population-based study of incidence, treatment strategies, and outcome in Swedish patients during 15 years	88
Colchicine and the heart	88
Elevated remnant cholesterol increases the risk of peripheral artery disease, myocardial infarction, and ischaemic stroke: a cohort-based study	87
Clonal haematopoiesis in chronic ischaemic heart failure: prognostic role of clone size for DNMT3A- and TET2-driver gene mutations	86
Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk	86
Comparative effects of guided vs. potent P2Y12 inhibitor therapy in acute coronary syndrome: a network meta-analysis of 61 898 patients from 15 randomized trials	85
Low-density lipoprotein cholesterol reduction and statin intensity in myocardial infarction patients and major adverse outcomes: a Swedish nationwide cohort study	84
Comparison of in-hospital outcomes and readmissions for valve-in-valve transcatheter aortic valve replacement vs. reoperative surgical aortic valve replacement: a contemporary assessment of real-world	83
Targeting muscle-enriched long non-coding RNA H19 reverses pathological cardiac hypertrophy	83
New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people	83
Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis	82
Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with th	82
Antiplatelet therapy in patients with conservatively managed spontaneous coronary artery dissection from the multicentre DISCO registry	82
Inclisiran and cardiovascular events: a patient-level analysis of phase III trials	81
Clinical characteristics and prognosis of patients with microvascular angina: an international and prospective cohort study by the Coronary Vasomotor Disorders International Study (COVADIS) Group	81
Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial	81
Post-stenting fractional flow reserve vs coronary angiography for optimization of percutaneous coronary intervention (TARGET-FFR)	81
Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes	81
Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease	81
Pathophysiologic importance of visceral adipose tissue in women with heart failure and preserved ejection fraction	81
Clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study	80
Cardiac arrest in COVID-19: characteristics and outcomes of in- and out-of-hospital cardiac arrest. A report from the Swedish Registry for Cardiopulmonary Resuscitation	80
The management of secondary mitral regurgitation in patients with heart failure: a joint position statement from the Heart Failure Association (HFA), European Association of Cardiovascular Imaging (EA	80
Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percuta	79
The effect of spironolactone on cardiovascular function and markers of fibrosis in people at increased risk of developing heart failure: the heart ‘OMics’ in AGEing (HOMAGE) randomized clinical trial	78
Intracoronary ALLogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial	78
Frailty and cardiovascular outcomes in the National Health and Aging Trends Study	77
Women who experience a myocardial infarction at a young age have worse outcomes compared with men: the Mass General Brigham YOUNG-MI registry	77
Calcific aortic valve disease: from molecular and cellular mechanisms to medical therapy	77
Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial	77
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial	77
Targeting early stages of cardiotoxicity from anti-PD1 immune checkpoint inhibitor therapy	77
The “ten commandments” for the 2021 ESC/EACTS Guidelines on valvular heart disease	76
Less dementia after catheter ablation for atrial fibrillation: a nationwide cohort study	76
Assessment and pathophysiology of microvascular disease: recent progress and clinical implications	76
Antithrombotic therapies in aortic and peripheral arterial diseases in 2021: a consensus document from the ESC working group on aorta and peripheral vascular diseases, the ESC working group on thrombo	75
Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction	75
The win ratio approach for composite endpoints: practical guidance based on previous experience	75
Heart failure with preserved ejection fraction in patients with normal natriuretic peptide levels is associated with increased morbidity and mortality	73
Imaging predictors of response to cardiac resynchronization therapy: left ventricular work asymmetry by echocardiography and septal viability by cardiac magnetic resonance	73
A practical risk score for early prediction of neurological outcome after out-of-hospital cardiac arrest: MIRACLE2	73
Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial	73
Incidence, risk factors, and mortality of atrial fibrillation in breast cancer: a SEER-Medicare analysis	73
Directly measured vs. calculated remnant cholesterol identifies additional overlooked individuals in the general population at higher risk of myocardial infarction	73
Chronic thromboembolic pulmonary hypertension and impairment after pulmonary embolism: the FOCUS study	73
CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure	72
Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial	72

Leadless vs. transvenous single-chamber ventricular pacing in the Micra CED study: 2-year follow-up	71
Effect of empagliflozin on circulating proteomics in heart failure: mechanistic insights into the EMPEROR programme	71
Return to sports after COVID-19 infection	71
The novel cystatin C, lactate, interleukin-6, and N-terminal pro-B-type natriuretic peptide (CLIP)-based mortality risk score in cardiogenic shock after acute myocardial infarction	70
Cardiovascular immunotoxicities associated with immune checkpoint inhibitors: a safety meta-analysis	70
The effect of intravenous ferric carboxymaltose on health-related quality of life in iron-deficient patients with acute heart failure: the results of the AFFIRM-AHF study	69
Recommendations for participation in competitive sport in adolescent and adult athletes with Congenital Heart Disease (CHD): position statement of the Sports Cardiology & Exercise Section of the E	69
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis	68
Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the He	68
Impact of empagliflozin on decongestion in acute heart failure: the EMPULSE trial	68
Heart failure with preserved ejection fraction in humans and mice: embracing clinical complexity in mouse models	68
Clinical characteristics and outcomes in childhood-onset hypertrophic cardiomyopathy	67
Triaging acute pulmonary embolism for home treatment by Hestia or simplified PESI criteria: the HOME-PE randomized trial	67
Midlife blood pressure is associated with the severity of white matter hyperintensities: analysis of the UK Biobank cohort study	67
Differential immunological signature at the culprit site distinguishes acute coronary syndrome with intact from acute coronary syndrome with ruptured fibrous cap: results from the prospective translat	67
Feasibility of using deep learning to detect coronary artery disease based on facial photo	66
The ‘10 commandments’ for the 2021 ESC guidelines on cardiac pacing and cardiac resynchronization therapy	66
Cardiac pacing in severe recurrent reflex syncope and tilt-induced asystole	66
Improved cardiovascular risk prediction using targeted plasma proteomics in primary prevention	66
Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data	66
Untargeted metabolomics identifies succinate as a biomarker and therapeutic target in aortic aneurysm and dissection	66
Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer—a nationwide analysis	65
The JAK–STAT pathway: an emerging target for cardiovascular disease in rheumatoid arthritis and myeloproliferative neoplasms	64
Assessing left ventricular systolic function: from ejection fraction to strain analysis	64
Predicted benefit of an implantable cardioverter-defibrillator: the MADIT-ICD benefit score	64
Outdoor light at night and risk of coronary heart disease among older adults: a prospective cohort study	63
A polygenic risk score improves risk stratification of coronary artery disease: a large-scale prospective Chinese cohort study	63
Phenotypic clustering of dilated cardiomyopathy patients highlights important pathophysiological differences	63
Evaluation of gene validity for CPVT and short QT syndrome in sudden arrhythmic death	62
Metoprolol exerts a non-class effect against ischaemia–reperfusion injury by abrogating exacerbated inflammation	62
COVID-19: from epidemiology to treatment	62
STING, a cytosolic DNA sensor, plays a critical role in atherogenesis: a link between innate immunity and chronic inflammation caused by lifestyle-related diseases	62
Road traffic noise and cardiovascular disease risk factors in UK Biobank	62
Sex differences in outcomes after coronary artery bypass grafting: a pooled analysis of individual patient data	61
Atrial fibrillation and kidney function: a bidirectional Mendelian randomization study	61
Brugada syndrome genetics is associated with phenotype severity	61
Genetic variability in the absorption of dietary sterols affects the risk of coronary artery disease	61
Targeting the CCL2–CCR2 axis for atheroprotection	61
Heart healthy cities: genetics loads the gun but the environment pulls the trigger	61
Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality	61
Sex differences in arterial hypertension	60
Stress-associated neurobiological activity associates with the risk for and timing of subsequent Takotsubo syndrome	60
Effects of canagliflozin on human myocardial redox signalling: clinical implications	59
Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement	59
The effect of intravenous ferric carboxymaltose on cardiac reverse remodelling following cardiac resynchronization therapy—the IRON-CRT trial	59
Catheter ablation vs. thoracoscopic surgical ablation in long-standing persistent atrial fibrillation: CASA-AF randomized controlled trial	59
Plasma angiotensin-converting enzyme 2: novel biomarker in heart failure with implications for COVID-19	59
Exercise-based cardiac rehabilitation for coronary heart disease: a meta-analysis	59
Obesity and weight loss are inversely related to mortality and cardiovascular outcome in prediabetes and type 2 diabetes: data from the ORIGIN trial	58
Acute mental stress drives vascular inflammation and promotes plaque destabilization in mouse atherosclerosis	58
Vegetarians, fish, poultry, and meat-eaters: who has higher risk of cardiovascular disease incidence and mortality? A prospective study from UK Biobank	58
TeleCheck-AF for COVID-19	58
Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology	58
Ticagrelor monotherapy in patients at high bleeding risk undergoing percutaneous coronary intervention: TWILIGHT-HBR	58
Association of β-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis	58
Lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1): a crucial driver of atherosclerotic cardiovascular disease	58
Prediction of ventricular arrhythmia in phospholamban p.Arg14del mutation carriers–reaching the frontiers of individual risk prediction	57
A possible explanation for the contrasting results of REDUCE-IT vs. STRENGTH: cohort study mimicking trial designs	57
High-density lipoprotein revisited: biological functions and clinical relevance	57
Does epicardial fat contribute to COVID-19 myocardial inflammation?	56
The dawn of a new era of targeted lipid-lowering therapies	56
Corrigendum to: 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary s	56
The struggle towards a Universal Definition of Heart Failure—how to proceed?	56
Critical appraisal of artificial intelligence-based prediction models for cardiovascular disease	55
Iron deficiency and cardiovascular disease	55
Association of the combined effects of air pollution and changes in physical activity with cardiovascular disease in young adults	55
Transition to adulthood and transfer to adult care of adolescents with congenital heart disease: a global consensus statement of the ESC Association of Cardiovascular Nursing and Allied Professions (A	55
Short-coupled ventricular fibrillation represents a distinct phenotype among latent causes of unexplained cardiac arrest: a report from the CASPER registry	55
Brugada syndrome and reduced right ventricular outflow tract conduction reserve: a final common pathway?	55
Targeted proteomics improves cardiovascular risk prediction in secondary prevention	55
Evolution of antithrombotic therapy in patients undergoing percutaneous coronary intervention: a 40-year journey	55
Sleep arousal burden is associated with long-term all-cause and cardiovascular mortality in 8001 community-dwelling older men and women	54
2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance	54
Long-term clinical outcomes of losartan in patients with Marfan syndrome: follow-up of the multicentre randomized controlled COMPARE trial	53
Five-year outcomes after state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: final results of the SYNTAX II study	53
Standardized exercise training is feasible, safe, and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension: results from a large European multicentre randomized controlled	53
Pulmonary vascular disease in pulmonary hypertension due to left heart disease: pathophysiologic implications	53
The association of amputations and peripheral artery disease in patients with type 2 diabetes mellitus receiving sodium-glucose cotransporter type-2 inhibitors: real-world study	53
Coronary flow velocity reserve predicts adverse prognosis in women with angina and no obstructive coronary artery disease: results from the iPOWER study	52
Robustness and relevance of predictive score in sudden cardiac death for patients with Brugada syndrome	52
Longitudinal strain is an independent predictor of survival and response to therapy in patients with systemic AL amyloidosis	52
Molecular imaging-guided repair after acute myocardial infarction by targeting the chemokine receptor CXCR4	52
Silent brain infarcts impact on cognitive function in atrial fibrillation	52
Two-year outcome after implantation of a full magnetically levitated left ventricular assist device: results from the ELEVATE Registry	50
Tilt testing remains a valuable asset	50
Restrictive cardiomyopathy: definition and diagnosis	50
PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction	50
Percutaneous coronary intervention in patients with cancer and readmissions within 90 days for acute myocardial infarction and bleeding in the USA	49
Genome-wide association analysis in dilated cardiomyopathy reveals two new players in systolic heart failure on chromosomes 3p25.1 and 22q11.23	49
Artificial intelligence in the diagnosis and management of arrhythmias	49
Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock	48
Renal denervation in the management of hypertension in adults. A clinical consensus statement of the ESC Council on Hypertension and the European Association of Percutaneous Cardiovascular Interventio	48
All-cause mortality and location of death in patients with established cardiovascular disease before, during, and after the COVID-19 lockdown: a Danish Nationwide Cohort Study	48
Silent brain infarcts and early cognitive outcomes after transcatheter aortic valve implantation: a systematic review and meta-analysis	48
Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials	48